A Phase 4 interventional study of Aspirin, acetaminophen and caffeine and Sumatriptan in Pain, Migraine, sponsored by Novartis. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-07-30.
Sponsored by Novartis · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 137 studies testing acetaminophen in Pain — 5 open to participants now, 5 under way, none of them phase 3. Acetaminophen · Pain.
Among the 137 studies testing acetaminophen in Pain, this one is the 4th largest by enrollment, is one of 6 that started in 2010, is one of 67 in phase 4, and was the 36th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →5 of the 137 studies testing acetaminophen in Pain are open now, in 3 countries. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
Horizon Health Network · Sites in Canada
Ages 19+
University of Gaziantep · Sites in Turkey
Ages 18–75
Western Galilee Hospital-Nahariya · Sites in Israel
Ages 18–45 · Women only · Healthy volunteers
Baskent University · Sites in Turkey
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
137 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 25 · Phase 4 67
First in 2003; this study’s year is marked. 6 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 752 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 95 across the 137 interventional studies. Of the 115 that completed or were terminated, 53 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 137 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
19 studies in Pain by Novartis: 1 open now, 1 under way, none of them phase 3. Of 17 finished, 3 (18%) have results posted.
Among the 19 studies in Pain by Novartis, this one has the largest enrollment, is the only one that started in 2010, is one of 10 in phase 4, and was the 16th registered.
Novartis’s Pain studies by the year they started, since 1998.
4 of the studies testing acetaminophen in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07512297University of GaziantepPain Control During ESWL Using Non-Opioid Analgesics | 2027-01-01 |
| NCT07368738Horizon Health NetworkIntravenous Acetaminophen and Ketorolac for Pain Management During Extracorporeal Shockwave Lithotripsy | 2027-04 |
| NCT06613178McGill University Health Centre/Research Institute of the McGill University Health CentreIntravenous Acetaminophen After Cardiac Surgery - Definitive Study | 2027-07-01 |
| NCT07536425Western Galilee Hospital-NahariyaPreoperative Indomethacin and Paracetamol for Pain Management During Oocyte Retrieval in IVF Patients | 2027-10-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 137 studies testing acetaminophen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 19 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to compare the efficacy and safety of aspirin, acetaminophen and caffeine (AAC) with sumatriptan and placebo in the acute treatment of migraine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Headache symptoms which may be due to or aggravated by:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AAC: 2 tablets, each containing acetaminophen 250 mg, aspiring 250 mg, caffeine 65 mg and 1 placebo tablet matching sumatriptan 100 mg tablets
Drug: Aspirin, acetaminophen and caffeine
1 tablet containing sumatriptan 100 mg and 2 placebo tablets matching acetaminophen 250 mg, aspirin 250 mg and caffeine 65 mg tablets
Drug: Sumatriptan
1 placebo tablet matching sumatriptan 100mg and 2 placebo tablets matching acetaminophen 250 mg, aspirin 250 mg and caffeine 65 mg tablets
Drug: Placebo
Drug pages: Aspirin · Acetaminophen · Caffeine
2 tablets each containing Aspirin (250mg), acetaminophen (250mg) and caffeine (65mg)
100 mg Sumatriptan
placebo
Percent of Subjects Who Are Pain Free at 2 Hours.
Subjects assessed severity of pain on a 4 point scale (0=none, ..., 3=severe) at set time points after dosing through 4 hours. Subjects who indicated severity of pain=none at 2 hours were considered pain free at 2 hours
Time frame: 2 hours
Percent of Subjects Who Are Free of Nausea at 2 Hours.
Subjects assessed severity of relevant symptom on a 4 point scale (0=none, ..., 3=severe) at set time points after dosing through 4 hours. Subjects who indicated severity of relevant symptom=none at 2 hours were considered relevant symptom free at 2 hours
Time frame: 2 hours
Percent of Subjects Who Are Free of Phonophobia at 2 Hours.
Subjects assessed severity of relevant symptom on a 4 point scale (0=none, ..., 3=severe) at set time points after dosing through 4 hours. Subjects who indicated severity of relevant symptom=none at 2 hours were considered relevant symptom free at 2 hours
Time frame: 2 hours
Percent of Subjects Who Are Free of Photophobia at 2 Hours.
Subjects assessed severity of relevant symptom on a 4 point scale (0=none, ..., 3=severe) at set time points after dosing through 4 hours. Subjects who indicated severity of relevant symptom=none at 2 hours were considered relevant symptom free at 2 hours
Time frame: 2 hours
| Milestone | Aspirin, Acetaminophen, and Caffeine | Sumatriptan (100 mg) | Placebo |
|---|---|---|---|
| Started | 299 | 304 | 149 |
| Safety population | 266 | 271 | 133 |
| Itt population | 256 | 261 | 125 |
| Completed | 284 | 290 | 145 |
| Not completed | 15 | 14 | 4 |
| Withdrew: Administrative problem | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 9 | 12 | 4 |
| Withdrew: Pregnancy | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 2 | 0 |
Subjects assessed severity of pain on a 4 point scale (0=none, ..., 3=severe) at set time points after dosing through 4 hours. Subjects who indicated severity of pain=none at 2 hours were considered pain free at 2 hours
| Percent of participants | Aspirin, Acetaminophen, and Caffeine | Sumatriptan (100 mg) | Placebo |
|---|---|---|---|
| Percent of Subjects Who Are Pain Free at 2 Hours. | 34.7 (.938 to 2.484) | 44.9 (0.431 to .900) | 26.4 (1.525 to 3.937) |
Subjects assessed severity of relevant symptom on a 4 point scale (0=none, ..., 3=severe) at set time points after dosing through 4 hours. Subjects who indicated severity of relevant symptom=none at 2 hours were considered relevant symptom free at 2 hours
| percent of participants | Aspirin, Acetaminophen, and Caffeine | Sumatriptan (100 mg) | Placebo |
|---|---|---|---|
| Percent of Subjects Who Are Free of Nausea at 2 Hours. | 70.6 (.863 to 2.522) | 72.2 (.662 to 1.506) | 66.4 (.856 to 2.549) |
Subjects assessed severity of relevant symptom on a 4 point scale (0=none, ..., 3=severe) at set time points after dosing through 4 hours. Subjects who indicated severity of relevant symptom=none at 2 hours were considered relevant symptom free at 2 hours
| Percent of participants | Aspirin, Acetaminophen, and Caffeine | Sumatriptan (100 mg) | Placebo |
|---|---|---|---|
| Percent of Subjects Who Are Free of Phonophobia at 2 Hours. | 53.4 (.904 to 2.353) | 60.9 (.630 to 1.334) | 46.2 (.977 to 2.590) |
Subjects assessed severity of relevant symptom on a 4 point scale (0=none, ..., 3=severe) at set time points after dosing through 4 hours. Subjects who indicated severity of relevant symptom=none at 2 hours were considered relevant symptom free at 2 hours
| Percent of participants | Aspirin, Acetaminophen, and Caffeine | Sumatriptan (100 mg) | Placebo |
|---|---|---|---|
| Percent of Subjects Who Are Free of Photophobia at 2 Hours. | 48.6 (.888 to 2.327) | 52.3 (.631 to 1.315) | 40.8 (.980 to 2.542) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aspirin, Acetaminophen, and Caffeine | — | 0/266 (0%) | 8/266 (3%) |
| Sumatriptan (100 mg) | — | 0/271 (0%) | 14/271 (5.2%) |
| Placebo | — | 0/133 (0%) | 3/133 (2.3%) |
| Event | Aspirin, Acetaminophen, and Caffeine | Sumatriptan (100 mg) | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 8/266 | 14/271 | 3/133 |
| Age Continuous(years) | Aspirin, Acetaminophen, and Caffeine | Sumatriptan (100 mg) | Placebo | Total |
|---|---|---|---|---|
| Mean | 38 ± 11.4 | 37.8 ± 11.4 | 37.6 ± 11.5 | 37.8 ± 11.4 |
| Sex: Female, Male(Participants) | Aspirin, Acetaminophen, and Caffeine | Sumatriptan (100 mg) | Placebo | Total |
|---|---|---|---|---|
| Female | 250 | 245 | 125 | 620 |
| Male | 49 | 59 | 24 | 132 |
| Race/Ethnicity, Customized(Participants) | Aspirin, Acetaminophen, and Caffeine | Sumatriptan (100 mg) | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 0 | 2 |
| Asian | 3 | 9 | 5 | 17 |
| Native Hawaiian or Other Pacific Islander | 1 | 2 | 0 | 3 |
| Black or African American | 44 | 47 | 24 | 115 |
| White | 244 | 239 | 113 | 596 |
| Other | 6 | 6 | 7 | 19 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Aspirin, Acetaminophen, and Caffeine | Sumatriptan (100 mg) | Placebo | Total |
|---|---|---|---|---|
| United States | 299 | 304 | 149 | 752 |
The record gives a start of Nov 2010, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2012, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aspirin · Acetaminophen · Caffeine